EMA Withdrawn: Imatinib Koanaa (imatinib mesilate) — Koanaa Healthcare GmbH

View source ↗

Summary

The EMA status shows Imatinib Koanaa (imatinib mesilate) has been withdrawn from the market by Koanaa Healthcare GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma
• Gastrointestinal Stromal Tumors
• Hypereosinophilic Syndrome
• Leukemia Myelogenous Chronic Bcr-abl Positive
• Myelodysplastic Myeloproliferative Diseases
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Imatinib Koanaa (imatinib mesilate)

Snippet

Status: Withdrawn. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;Dermatofibrosarcoma;Gastrointestinal Stromal Tumors. MAH: Koanaa Healthcare GmbH. Decision date: 22/09/2021